Dermatology· Topic 3.2 Immune-mediated skin disease· 3.2.8

Pemphigus vulgaris

Pemphigus vulgaris is an autoimmune intraepidermal blistering disease in which IgG autoantibodies against desmoglein 3, often with desmoglein 1, destroy keratinocyte adhesion, producing flaccid, easily ruptured mucocutaneous bullae with a positive Nikolsky sign. Diagnosis is confirmed by skin biopsy with direct immunofluorescence and anti-desmoglein serology, and first-line treatment is rituximab 1,000 mg IV twice, two weeks apart, combined with a tapering corticosteroid course.

10 min read1 practice questions8 key factsSubscriber article
  • Topic review
    The full article, organized the way the exam asks it.
  • ABIM-format MCQs
    Vignettes with an explanation for every wrong answer.
  • Key facts
    The numbers and thresholds worth memorizing, up front.
  • AI tutor
    MedBrain answers the question you're stuck on.

What this article covers

  • Overview

    Definition: pemphigus vulgaris is an autoimmune, antibody-mediated (type II) hypersensitivity blistering disease in which IgG antibodies attack desmoglein 3, often together with desmoglein 1, the…

  • Epidemiology

    Incidence: estimated at 0.5 to 3.2 cases per 100,000 persons per year, rising further with older age.

  • Risk factors

    Ashkenazi Jewish ancestry: the strongest recognized demographic association.

  • Pathophysiology

    Type II hypersensitivity against desmosomes: IgG autoantibodies target desmoglein 3, and often desmoglein 1, the cadherin-family adhesion proteins of the desmosome that provide structural support through intermediate filament interactions.

  • Clinical features

    Diagnostic pattern: flaccid oral or other mucosal bullae that rupture easily to leave painful, irregularly bordered erosions, together with a positive Nikolsky sign (lateral pressure on perilesional…

  • Differential diagnosis

    Paraneoplastic pemphigus: painful oral, conjunctival, esophageal, and laryngeal erosions with a polymorphous eruption and possible fatal respiratory involvement, unlike the mucocutaneous-only disease…

  • Diagnosis

    Diagnose with skin biopsy plus direct immunofluorescence and confirm with serology: the clinching basis is a perilesional skin biopsy showing suprabasilar acantholysis (the "row of tombstones"…

  • Management

    First, screen for hepatitis B with HBsAg and anti-HBc before initiating first-line B-cell-depleting therapy, since hepatitis B reactivation is a recognized risk of this treatment.

  • Complications

    Death from infection or disease severity if untreated: before effective immunosuppressive treatment, mortality from pemphigus vulgaris was high, and it remains possible today, particularly from infection.

  • Prognosis

    Mortality was high before modern immunosuppression and changed once oral glucocorticoids and steroid-sparing agents became standard, though death remains possible today.

  • Prevention

    Screen hepatitis B (HBsAg and anti-HBc) before every course of rituximab to identify patients at risk for reactivation before B-cell-depleting therapy.

Read the whole article

Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.